STUDY DESIGN

The phase 2b IRX-2 Neoadjuvant Therapy in Head and Neck SCC to Provide Immune Response Enhancement (INSPIRE) study is a randomized, multicenter, multinational clinical trial intended to enroll approximately 200 patients with stage II, III, or IVA untreated squamous cell cancer (SCC) of the oral cavity who are candidates for resection with curative intent (NCT02609386).

STUDY SCHEMA

IRX-2 NEOADJUVANT DOSING SCHEDULE

STUDY DETAILS

© 2017 IRX Therapeutics